Business Wire

Proteintech Germany triples its space with a new office and laboratory

20.3.2024 21:57:00 EET | Business Wire | Press release

Share

Proteintech, the benchmark in antibodies and life science solutions, announces that its branch in Martinsried near Munich has moved into its new laboratory and office space. The new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320643097/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Proteintech celebrates the opening with a ribbon cutting event. Pictured: Dr. Jason Li, CEO of Proteintech, along with Proteintech executives and local government officials. (Photo: Business Wire)

In 2020, the Proteintech Group acquired ChromoTek GmbH, which specializes in the development and production of Nanobody-based reagents and was located at the incubator IZB. The gradual integration of Chromotek into the parent company, Proteintech Group, enabled new sales markets and channels for the products manufactured in Martinsried. The Martinsried site also serves as a central logistics hub for all Proteintech products for customers in the European Union.

Rainer Gebhart, Site Manager at Proteintech Germany, said: “Here we offer state-of-the-art working environments for daily top performance and innovation of our employees - our most important capital for a continued successful future.” He also explained, “The move supports our customer focused strategy. With a larger team in Martinsried – and in cooperation with our sister site in Manchester, UK – we can better serve our customers in Europe and further gain market share.”

Dr Jason Li, CEO of Proteintech said, “There is a great future for Nanobody technology and we’re excited to be at the forefront of this.” He also stated, “Proteintech has R&D and production laboratories on three continents in its major sites (Chicago, Wuhan and Martinsried). All three sites have seen expansion in the past year and the collaboration between them means we can bring new and innovative products to the market.”

About Proteintech Group

Proteintech Group Inc., founded in 2001, is a leading manufacturer of antibodies, proteins, nanobodies, and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. Proteintech offers antibodies, proteins and immunoassays across research areas with over 200,000 products cited. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001 accredited.

To learn more about Proteintech, please visit www.ptglab.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Katie Bellows
katie@ptglab.com
ph. +1-312-455-8498

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries18.8.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively. Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and Nepal, exceeding the program’s original scope by approximately 150 patients and helping establish access to innovative cancer care for patients who previo

Quectel Launches Android 16 Smart Modules for 4G and 5G IoT Devices18.8.2026 11:00:00 EEST | Press release

Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of two new Android 16 smart modules: the SH602FA, a high-performance 4G smart module, and the SE505FE, an entry-level 5G smart module. Designed for industrial and commercial IoT applications, the new modules combine Android 16, integrated wireless connectivity and powerful multimedia capabilities in compact form factors that simplify development and accelerate time-to-market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818272981/en/ Quectel launches Android 16 smart modules for 4G and 5G IoT devices By bringing Android 16 to both 4G and 5G IoT devices, Quectel enables developers to build smarter connected products with richer user interfaces, enhanced multimedia performance and seamless integration into modern smart building, retail and industrial environments. Android 16 enables connected devices to communicate more inte

Beno Opens Luxury Waterfront Guest Lounge at Marsa Al Arab in Partnership with Jumeirah Group18.8.2026 10:00:00 EEST | Press release

Beno, Dubai's luxury experiences platform, announced the opening of a new premium guest lounge at Marsa Al Arab, developed in partnership with Jumeirah Group, the hospitality arm of Dubai Holding. The lounge adds a permanently staffed guest-services layer to one of Dubai's newest ultra-luxury marine developments. Marsa Al Arab Marina, operated by D-Marin adjacent to Jumeirah Burj Al Arab, offers 82 berths for yachts of up to 61 metres and holds Superyacht Ready and Blue Flag certifications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818185241/en/ Beno's guest lounge on the marina promenade at Marsa Al Arab, Dubai, with the 115-ft yacht Santorini berthed opposite (Photo: AETOSWire) Beno coordinates yacht charters from the lounge, supported by a nine-vessel fleet berthed at the marina. Among them is Santorini, a 115-ft superyacht featuring five cabins that can accommodate up to 12 overnight guests and up to 80 guests fo

Queue-it Announces Majority Investment from THL Partners18.8.2026 10:00:00 EEST | Press release

Queue-it, a global provider of online traffic orchestration solutions, today announced that it has entered a definitive agreement for a majority investment from THL Partners (“THL”), a premier investment firm investing in middle-market growth companies. Together, THL and Queue-it will focus on accelerating product innovation and expanding the company’s global reach. Founded and headquartered in Denmark, Queue-it helps enterprises and public organizations manage online traffic surges, protect digital infrastructure, mitigate bots and abuse, and deliver fair, reliable access to critical online services. Its platform is trusted by organizations around the world and operates across ticketing, retail, government, financial services, and other mission-critical industries. THL’s partnership with Queue-it builds on the firm’s longstanding investment focus on IT Operations & Data, which includes software companies that help organizations operate, secure, and optimize increasingly complex digita

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 22:44:00 EEST | Press release

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye